Rosenfeld Manuela, Ladiges Warren
Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA 98195, USA.
Aging Pathobiol Ther. 2022;4(2):51-52. doi: 10.31491/apt.2022.06.086. Epub 2022 Jun 30.
Slowing human aging with pharmaceuticals is now recognized as a feasible strategy. However, the design of clinical trials is still focused on single drug approaches. The process of aging has multiple pathways, which no current drug has been shown to effectively target. Therefore, it is of interest to study combinations, or cocktails, of drugs. A recently published article reported that a drug cocktail of rapamycin, acarbose and phenylbutyrate slowed aging in middle-aged mice treated for three months. The impact of this report is discussed, with the implications for determining endpoints in humans for testing drug cocktails as well as testing other drug combinations.
利用药物减缓人类衰老现已被认为是一种可行的策略。然而，临床试验的设计仍集中在单一药物方法上。衰老过程有多种途径，目前尚无药物被证明能有效针对这些途径。因此，研究药物组合或鸡尾酒疗法很有意义。最近发表的一篇文章报道，雷帕霉素、阿卡波糖和苯丁酸盐的药物鸡尾酒疗法使接受了三个月治疗的中年小鼠的衰老减缓。本文讨论了该报告的影响，以及其对确定人体中测试药物鸡尾酒疗法及其他药物组合的终点指标的意义。
